Biological processes are full of variations
and so are responses to therapy as measured
in clinical research. Estimators of clinical efficacy
are, therefore, usually reported with a
measure of uncertainty, otherwise called dispersion.
This study aimed to review both the
flaws of data reports without measure of dispersion
and those with over-dispersion.
Examples of estimators commonly reported
without a measure of dispersion include:
1) number needed to treat;
2) reproducibility of quantitative diagnostic
tests;
3) sensitivity/specificity;
4) Markov predictors;
5) risk profiles predicted from multiple
logistic models.
Data with large differences between
response magnitudes can be assessed for
over-dispersion by goodness of fit tests. The c2
goodness of fit test allows adjustment for overdispersion.
For most clinical estimators, the calculation of standard errors or confidence intervals is
possible. Sometimes, the choice is deliberately
made not to use the data fully, but to skip the
standard errors and to use the summary measures
only. The problem with this approach is
that it may suggest inflated results. We recommend
that analytical methods in clinical
research should always attempt to include a
measure of dispersion in the data. When large
differences exist in the data, the presence of
over-dispersion should be assessed and appropriate
adjustments made.
Clinical research, uncertainty, standard error, confidence interval, sensitivity, specificity, reproducibility, Markov model, numbers needed to treat, logistic models, risk profiles, over-dispersion, variance inflating factor.
Ton J. Cleophas, Department Statistics, Circulation, Boston MA, c/o Department Medicine, Albert Schweitzer Hospital, Box 444, 3300 AK, Dordrecht, Netherlands. E-mail: ajm.cleophas@wxs.nl
2010-01-27
Trending Topic
This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]
Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 ...
Summary Few clinical studies have shown an association between coronary artery disease (CAD) and osteoporosis. This cross-sectional study has shown that, among Indian postmenopausal women, the prevalence of CAD increases across lower bone mineral density categories. Femoral neck osteoporosis confers ...
Glucagon-like peptide 1 (GLP-1) receptor agonists piqued our interest when Marso et al. demonstrated that liraglutide significantly reduced cardiovascular events (CVEs) in persons with type 2 diabetes mellitus (T2DM) who were at a high cardiovascular (CV) risk compared with placebo in ...
Over the past two decades, the field of transcatheter aortic valve replacement (TAVR) has experienced remarkable advancement. Initially approved for patients with high and prohibitive surgical risk, TAVR has progressively extended its indications to all patients, regardless of surgical risk. ...
Cardiovascular disease (CVD) continues to be the leading cause of death on a global scale. Nearly 18 million people died from CVD in 2019, accounting for about one-third of all deaths globally.1 The primary cause of CVD-related death and morbidity is ischaemic ...
With the global increase in life expectancy, the proportion of elderly people in the community is expected to increase gradually. This is referred to as the 'Coming of the Gray Dawn' or the 'Gray Wave', and highlights the need for ...
Cardiac complications constitute a common cause of morbidity and mortality in the perioperative period, contributing to over a third of perioperative deaths.1 More than 230 million major surgeries are performed annually worldwide, with older patients representing an increasing proportion of the ...
Diabetes mellitus (DM) is strongly associated with severe macro- and micro-vascular complications; it is also proven to be a strong independent risk factor for developing heart failure (HF).1 In fact, the prevalence of DM is reported to be as high ...
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality both in the US and worldwide.1 There is substantial evidence from genetic, observational and interventional studies that low-density lipoprotein cholesterol (LDL-C) is causally related to the development of ASCVD in ...
The prevalence of aortic stenosis (AS) has grown over the last few decades, as life expectancy has increased. AS is the most common valvular disease in the developed world and is found in up to 9.8% of individuals aged ≥75.1–3 The wide ...
Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease affecting 1 in 500 individuals worldwide.1 The disease pathogenesis of HCM is characterized by hypertrophy and myocyte disarray, along with muscle fibrosis on histopathology and intramural hyperplasia of the coronary arteries.2 HCM is diagnosed ...
The systemic amyloidoses are a group of heterogenous diseases, which are characterized by the deposition of insoluble amyloid fibrils within the extracellular matrix of multiple organs throughout the body. Amyloid fibrils are formed from the misfolding of amyloid precursor proteins (...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.